|1.||Schunack, W: 2 articles (04/2002 - 10/2000)|
|2.||Poli, E: 1 article (04/2002)|
|3.||Pozzoli, C: 1 article (04/2002)|
|4.||Coruzzi, G: 1 article (04/2002)|
|5.||Lazzaretti, M: 1 article (04/2002)|
|6.||Nosalova, V: 1 article (04/2002)|
|7.||Grandi, D: 1 article (04/2002)|
|8.||Rouleau, A: 1 article (10/2000)|
|9.||Schwartz, J C: 1 article (10/2000)|
|10.||Stark, H: 1 article (10/2000)|
|1.||Asthma (Bronchial Asthma)
08/01/2000 - "BP-294 (a prodrug of R-alpha-methylhistamine) is a histamine-H(3) agonist under development by Bioprojet, which is currently in phase II clinical trials as a potential treatment for asthma ."
06/01/1997 - "From its pharmacokinetics and pharmacological profile BP 2-94 appears to be a promising novel therapeutic agent in disorders such as asthma, migraine or a variety of inflammatory diseases and pain associated with these disorders."
|3.||Migraine Disorders (Migraine)
12/01/1999 - "After intragastric administration of BP 2-94 (10 mg/kg), both the prodrug and (R)-alpha-methylhistamine were detected in plasma: plasma levels of (R)-alpha-methylhistamine decayed with a T1/2 of about 1 hr and displayed concentrations as high as 50-fold the EC50 of the drug at the H3 receptor for at least 2 hr. In conscious dogs provided with gastric fistula BP 2-94, administered at 10 and 30 mg/kg intragastrically, caused a dose-dependent inhibition (maximum reduction was about 80%) of the acid secretion stimulated by 2-deoxy-D-glucose, whereas (R)-alpha-methylhistamine (20 mg/kg, intragastrically) was ineffective. "
|2.||Histamine (Histamine Dihydrochloride)
|3.||Dihydrotachysterol (AT 10)
|4.||Deoxyglucose (2 Deoxy D glucose)